Marine Depsipeptide Nobilamide I Inhibits Cancer Cell Motility and Tumorigenicity via Suppressing Epithelial-Mesenchymal Transition and MMP2/9 Expression.
Tu Cam LeSultan PulatJihye LeeGeum Jin KimHaerin KimEun-Young LeePrima F HillmanHyukjae ChoiInho YangDong-Chan OhHangun KimSang-Jip NamWilliam FenicalPublished in: ACS omega (2022)
A cyclic depsipeptide, nobilamide I ( 1 ), along with the known peptide A-3302-B/TL-119 ( 2 ), was isolated from the saline cultivation of the marine-derived bacterium Saccharomonospora sp., strain CNQ-490. The planar structure of 1 was elucidated by interpretation of 1D and 2D NMR and MS spectroscopic data. The absolute configurations of the amino acids in 1 were assigned by using the C 3 Marfey's analysis and comparing them with those of 2 based on their biosynthetic pathways. Nobilamide I ( 1 ) decreased cell motility by inhibiting epithelial-mesenchymal transition markers in A549 (lung cancer), AGS (gastric cancer), and Caco2 (colorectal cancer) cell lines. In addition, 1 modulated the expression of the matrix metalloproteinase (MMP) family (MMP2 and MMP9) in the three cell lines.
Keyphrases
- epithelial mesenchymal transition
- signaling pathway
- poor prognosis
- cell migration
- transforming growth factor
- amino acid
- biofilm formation
- mass spectrometry
- multiple sclerosis
- ms ms
- single cell
- binding protein
- long non coding rna
- stem cells
- electronic health record
- cell therapy
- machine learning
- staphylococcus aureus
- pseudomonas aeruginosa
- candida albicans
- mesenchymal stem cells